Susan C. Fagan, Pharm.D., BCPS, FCCP

Professor

Clinical and Administrative Pharmacy
University of Georgia College of Pharmacy and
Medical College of Georgia
CJ-1020, Augusta, Georgia 30912-2450
E-mail: sfagan@mail.mcg.edu

Education:

1980   B.Sc. Pharmacy
Dalhousie University, Halifax, Canada
1984   Pharm.D.
SUNY at Buffalo, NY
1986   Fellowship (Neuropharm)
Dent Neurologic Institute, Buffalo, NY

Research Interests:

Stroke pharmacotherapy; in particular, animal models of ischemic stroke, hemorrhagic transformation of cerbral ischemia, new treatments for stroke, stroke outcomes

Selected Publications

The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997;28:2109-2118.

The NINDS t-PA Stroke Study Group: Generalized efficacy of t-PA for Acute Stroke: Subgroup analysis of the NINDS t-PA Stroke Trial. Stroke 1997;28:2119-2125.

Knight, R.A., Barker, P.B., Fagan, S.C., Li, Y., Jacobs, M.A., Welch, K.M.A. Prediction of impending hemorrhagic transformation in ischemic stroke using Magnetic Resonance Imaging. Stroke 1998;29:144-151.

Fagan, S.C., Bowes, M.P., Lyden, P.D., Zivin, J.A. Acute hypertension promotes hemorrhagic infarction in a rabbit embolic stroke model. Effect of labetalol. Exp Neurol 1998;150:153-158.

Fagan, S.C., Morgenstern, L.B., Petitta, A., Ward, R.E., Tilley, B.C., Marler, J.R., Levine, S.R., Broderick, J.P., Kwiatkowski, T., Frankel, M., Walker, M.D. and the NINDS rt-PA Stroke Study Group.Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology 1998;50:883-890.

Brott, T.G., Lu, M., Kothari, R., Fagan, S.C., Frankel, M., Grotta, J.C., Broderick, J., Kwiatkowski, T., Lewandowski, C., Haley, E.C., Marler, J.R., Tilley, B.C. Hypertension and its treatment in the NINDS t-PA Stroke Study. Stroke 1998;29:1504-1509.

Rahill A, Brown GG, Fagan SC, Ewing JR, Branch CA, Balakrishnan G : Neuropsychological dose effects of a Freon, trifluoromethane(FC-23), compared to N2O. Neurotoxicology and Teratology 1998;20:617-626.

Fagan SC, Rhoney DH: Countering the rising incidence of stroke. American Druggist (Invited) 1998; Oct.:64-71.

Fagan, S.C., Garcia, J.H. Hemorrhagic transformation in focal cerebral ischemia: Effect of time to artery reopening and tissue plasminogen activator. Pharmacotherapy 1999;19:139-142.

Fagan, S.C., Bowes, M.P., Berri, S., Zivin, J.A. Combination therapy for acute ischemic stroke: A ray of hope. J Stroke Cerebrovasc Dis, 1999;8:359-367.

Ng TMH, Kohli A, Fagan SC, Mohamed AE, Geiszt G: The effect of intravenous verapamil on cerebral hemodynamics in a migraine patient with hemiplegia. Ann Pharmacother 2000; 34 : 39-43.

Brott TG, Grotta JC, Latchaw RE, Starkman S, Jauch E, Clark WM, Fagan SC, Hopkins LN: Stroke The First Hours. Consensus Statement. October, 2000; National Stroke Association.

Hess DC, Fagan SC: Pharmacology and clinical experience with simvastatin. Exp Opinion in Pharmacother 2001;2(1):153-163.

Fagan SC: Hemorrhagic transformation after reperfusion therapy for acute ischemic stroke. J Inform Pharmacother 2001;4:300-305.

Fagan S. The International Stroke Trial: What "IS" the Best Therapy for Acute Ischaemic Stroke? J Inform Pharmacother 2001;5:213-215.

Grotta JC, Welch KMA, Fagan SC, Lu M, Frankel MR, Brott T, Levine SR, Lyden PD and the NINDS rt-PA Stroke Study Group. Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial. Stroke 2001;32:661-668.

Broderick J, Lu M, Jackson C, Pancioli A, Tilley BC, Fagan SC, Kothari R, Levine SR, Marler JR, Lyden PD, Haley EC, Brott TG, Grotta J and the NINDS rt-PA Stroke Study Group: Apolipoprotein E phenotype and the efficacy of tissue plasminogen activator in acute ischemic stroke. Ann Neurol 2001; 49:736-744.

Sinclair SE, Frighetto L, Loewen P, Sunderji R, Teal P, Fagan SC, Marra CA: Cost-Utility analysis of tPA therapy for acute ischemic stroke. A Canadian healthcare perspective. Pharmacoeconomics 2001;19(9):927-36.

Lyden P, Lu M, Kwiatkowski T, Frankel M, Levine S, Broderick J, Brott T and the NINDS rt-PA Stroke Study Group: Thrombolysis in patients with transient Neurologic deficits. Neurology 2001;57:2125-2128.

[ ABOUT THE COLLEGE | ADMISSIONS | ACADEMICS | ALUMNI AFFAIRS | CE | DEVELOPMENT | RESOURCES ]